CFH Specific Neutra™ Antibody Products

Are you struggling to overcome challenges in complement-mediated drug development, such as prolonged timelines or inconsistent target validation? Creative Biolabs' CFH specific Neutra™ antibody products leverage advanced recombinant engineering to deliver highly specific, affinity-validated antibodies, enabling efficient identification of therapeutic candidates and robust functional analysis.

Introduction to CFH

Complement Factor H (CFH) is a critical regulatory protein in the complement system, primarily synthesized in the liver and secreted into plasma. This soluble glycoprotein modulates the alternative pathway (AP) by inhibiting excessive complement activation, preventing unintended host tissue damage. CFH's role in maintaining immune homeostasis makes it a pivotal target for therapies addressing complement dysregulation.

• Structure

CFH comprises 20 short consensus repeat (SCR) domains, each containing approximately 60 amino acids. SCR domains 1-4 mediate cofactor activity for C3b cleavage, while SCR 19-20 bind polyanions on host cell surfaces, enabling self/non-self discrimination. Structural studies reveal that mutations in SCR domains—particularly SCR 7, 20, and 23—disrupt regulatory functions, contributing to pathological conditions.

• Related Signaling Pathways

CFH directly inhibits the AP by competing with Factor B for C3b binding, accelerating decay of the C3 convertase (C3bBb), and acting as a cofactor for Factor I-mediated C3b cleavage. Dysregulation disrupts the delicate balance between complement activation and inhibition, leading to uncontrolled inflammation and tissue injury.

Fig.1 Role of CFH within the complement system.¹

• Associated Diseases

CFH deficiencies or mutations are linked to severe disorders, including age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), and C3 glomerulopathy. In AMD, CFH polymorphisms (e.g., Y402H) impair retinal protection, promoting inflammation-driven macular damage. In aHUS, defective CFH enables complement hyperactivation on endothelial cells, triggering thrombotic microangiopathy.

Applications of CFH Neutralizing Antibodies

• Mechanistic Insights into Complement-Driven Disorders

CFH-neutralizing antibodies enable researchers to dissect pathological mechanisms in AMD, aHUS, and glomerulopathies. By blocking CFH's regulatory activity, these antibodies replicate disease-specific complement dysregulation in cellular assays, aiding target identification and validation.

• Therapeutic Candidate Screening

In drug development, CFH antibodies serve as critical controls for evaluating monoclonal therapies or small molecules designed to modulate complement activity. For example, anti-CFH antibodies validate inhibitors targeting AP dysregulation in preclinical models of aHUS or C3 glomerulopathy.

• Diagnostic Biomarker Development

Quantifying CFH levels or function in patient sera using neutralizing antibodies supports biomarker discovery for diseases like AMD. Assays incorporating these antibodies enhance diagnostic accuracy by correlating CFH activity with disease progression.

• Preclinical Models of Inflammatory Injury

Anti-CFH antibodies induce controlled complement activation in animal models, mimicking human pathologies such as ischemia-reperfusion injury or dense deposit disease. These models are indispensable for testing anti-complement therapies.

Our Anti-CFH Neutralizing Antibodies

Creative Biolabs' CFH-specific neutralizing antibodies are engineered to bind distinct functional epitopes, such as SCR 19-20 or C3b-binding regions. These antibodies enable:

- Quantitative detection of CFH in plasma or tissue samples via ELISA or Western blot.

- Functional blockade of CFH to study AP activation kinetics in vitro.

- Validation of therapeutic candidates targeting CFH in autoimmune or inflammatory models.

Key advantages include high batch-to-batch consistency, species cross-reactivity (human, primate, murine), and validated performance in flow cytometry and immunohistochemistry.

Creative Biolabs' CFH specific Neutra™ antibody products empower researchers to overcome complement-related challenges with industry-leading specificity and reproducibility. Contact our team today to discuss your project requirements and explore tailored solutions for accelerating therapeutic discovery.

REFERENCE

1. Sánchez-Corral, Pilar, et al. "Self-damage caused by dysregulation of the complement alternative pathway: relevance of the factor H protein family." Frontiers in immunology 9 (2018): 1607. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2018.01607